Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 32, 2013, Pages 12984-12989

  Silvestre, Hernani Leonardo ^a   Blundell, Thomas L ^a   Abell, Chris ^a   Ciulli, Alessio ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Drug design; Hot spots; Protein ligand interactions

Indexed keywords

PANTOTHENATE SYNTHETASE; SYNTHETASE; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; DRUG DEVELOPMENT; DRUG SCREENING; FRAGMENT BASED DRUG DISCOVERY; FRAGMENT BASED DRUG SCREENING; ISOTHERMAL TITRATION CALORIMETRY; MYCOBACTERIUM TUBERCULOSIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; VALIDATION PROCESS; X RAY ANALYSIS; X RAY CRYSTALLOGRAPHY;

DRUG DESIGN; HOT SPOTS; PROTEIN-LIGAND INTERACTIONS;

BACTERIAL PROTEINS; BINDING SITES; BIOPHYSICS; CALORIMETRY; CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; ENZYME INHIBITORS; KINETICS; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MYCOBACTERIUM TUBERCULOSIS; PEPTIDE SYNTHASES; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTEIN UNFOLDING; SMALL MOLECULE LIBRARIES; TEMPERATURE;

EID: 84881423067     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1304045110     Document Type: Article

References (49)

1. Congreve M, Murray CW, Carr R, Rees DC (2007) Fragment-based lead discovery. Annu Rep Med Chem 42:431-448.
2. Ciulli A, Abell C (2007) Fragment-based approaches to enzyme inhibition. Curr Opin Biotechnol 18(6):489-496.
3. Rees DC, Congreve M, Murray CW, Carr R (2004) Fragment-based lead discovery. Nat Rev Drug Discov 3(8):660-672.
4. Erlanson DA (2006) Fragment-based lead discovery: A chemical update. Curr Opin Biotechnol 17(6):643-652.
5. Hajduk PJ, Greer J (2007) A decade of fragment-based drug design: Strategic advances and lessons learned. Nat Rev Drug Discov 6(3):211-219.
6. Congreve M, Chessari G, Tisi D, Woodhead AJ (2008) Recent developments in fragment- based drug discovery. J Med Chem 51(13):3661-3680.
7. Chessari G, Woodhead AJ (2009) From fragment to clinical candidate-A historical perspective. Drug Discov Today 14(13-14):668-675.
8. Murray CW, Rees DC (2009) The rise of fragment-based drug discovery. Nat Chem 1(3): 187-192.
9. Erlanson DA, McDowell RS, O'Brien T (2004) Fragment-based drug discovery. J Med Chem 47(14):3463-3482.
10. Ciulli A, Blundell TL, Abell C (2008) Computational and Structural Approaches to Drug Discovery: Ligand-Protein Interactions, eds Stroud RM, Finer-Moore J (Royal Society of Chemistry, London), pp 293-318.
11. Jhoti H, Cleasby A, Verdonk M, Williams G (2007) Fragment-based screening using X-ray crystallography and NMR spectroscopy. Curr Opin Chem Biol 11(5):485-493.
12. Pellecchia M, et al. (2008) Perspectives on NMR in drug discovery: A technique comes of age. Nat Rev Drug Discov 7(9):738-745.
13. Blundell TL, Jhoti H, Abell C (2002) High-throughput crystallography for lead discovery in drug design. Nat Rev Drug Discov 1(1):45-54.
14. Hartshorn MJ, et al. (2005) Fragment-based lead discovery using X-ray crystallography. J Med Chem 48(2):403-413.
15. Erlanson DA, et al. (2000) Site-directed ligand discovery. Proc Natl Acad Sci USA 97(17):9367-9372.
16. Teotico DG, et al. (2009) Docking for fragment inhibitors of AmpC β-lactamase. Proc Natl Acad Sci USA 106(18):7455-7460.
17. Barker J, Courtney S, Hesterkamp T, Ullmann D, Whittaker M (2006) Fragment screening by biochemical assay. Expert Opin Drug Discov 1(3):225-236.
18. Ciulli A, Williams G, Smith AG, Blundell TL, Abell C (2006) Probing hot spots at proteinligand binding sites: A fragment-based approach using biophysical methods. J Med Chem 49(16):4992-5000.
19. 2 by computational and NMR screening and thermodynamic evaluation. Proteins 67(4):981-990.
20. Chen Y, Shoichet BK (2009) Molecular docking and ligand specificity in fragmentbased inhibitor discovery. Nat Chem Biol 5(5):358-364.
21. Pröll F, Fechner P, Proll G (2009) Direct optical detection in fragment-based screening. Anal Bioanal Chem 393(6-7):1557-1562.
22. Janin YL (2007) Antituberculosis drugs: Ten years of research. Bioorg Med Chem 15(7): 2479-2513.
23. Sambandamurthy VK, et al. (2002) A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nat Med 8(10):1171-1174.
24. Sambandamurthy VK, et al. (2006) Mycobacterium tuberculosis DeltaRD1 DeltapanCD: A safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis. Vaccine 24(37-39):6309-6320.
25. Zheng R, Blanchard JS (2001) Steady-state and pre-steady-state kinetic analysis of Mycobacterium tuberculosis pantothenate synthetase. Biochemistry 40(43):12904-12912.
26. Zheng R, Dam TK, Brewer CF, Blanchard JS (2004) Active site residues in Mycobacterium tuberculosis pantothenate synthetase required in the formation and stabilization of the adenylate intermediate. Biochemistry 43(22):7171-7178.
27. Wang S, Eisenberg D (2003) Crystal structures of a pantothenate synthetase from M. tuberculosis and its complexes with substrates and a reaction intermediate. Protein Sci 12(5):1097-1108.
28. Wang S, Eisenberg D (2006) Crystal structure of the pantothenate synthetase from Mycobacterium tuberculosis, snapshots of the enzyme in action. Biochemistry 45(6):1554-1561.
29. Velaparthi S, et al. (2008) 5-tert-butyl-N-pyrazol-4-yl-4,5,6,7- tetrahydrobenzo[d]isoxazole- 3-carboxamide derivatives as novel potent inhibitors of Mycobacterium tuberculosis pantothenate synthetase: Initiating a quest for new antitubercular drugs. J Med Chem 51(7):1999-2002.
30. White EL, et al. (2007) A novel inhibitor of Mycobacterium tuberculosis pantothenate synthetase. J Biomol Screen 12(1):100-105.
31. Tuck KL, Saldanha SA, Birch LM, Smith AG, Abell C (2006) The design and synthesis of inhibitors of pantothenate synthetase. Org Biomol Chem 4(19):3598-3610.
32. Ciulli A, et al. (2008) Inhibition of Mycobacterium tuberculosis pantothenate synthetase by analogues of the reaction intermediate. ChemBioChem 9(16):2606-2611.
33. Scott DE, Dawes GJ, Ando M, Abell C, Ciulli A (2009) A fragment-based approach to probing adenosine recognition sites by using dynamic combinatorial chemistry. ChemBioChem 10(17):2772-2779.
34. Hung AW, et al. (2009) Application of fragment growing and fragment linking to the discovery of inhibitors of Mycobacterium tuberculosis pantothenate synthetase. Angew Chem Int Ed Engl 48(45):8452-8456.
35. Sledz P, et al. (2010) Optimization of the interligand Overhauser effect for fragment linking: Application to inhibitor discovery against Mycobacterium tuberculosis pantothenate synthetase. J Am Chem Soc 132(13):4544-4545.
36. Lo M-C, et al. (2004) Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. Anal Biochem 332(1):153-159.
37. McDonnell PA, et al. (2009) Assessing compound binding to the Eg5 motor domain using a thermal shift assay. Anal Biochem 392(1):59-69.
38. Dalvit C, Fogliatto G, Stewart A, Veronesi M, Stockman B (2001) WaterLOGSY as a method for primary NMR screening: Practical aspects and range of applicability. J Biomol NMR 21(4):349-359.
39. Mayer M, Meyer B (1999) Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew Chem Int Ed 38(12):1784-1788.
40. Abdel-Rahman N, Martinez-Arias A, Blundell TL (2011) Probing the druggability of protein-protein interactions: Targeting the Notch1 receptor ankyrin domain using a fragment-based approach. Biochem Soc Trans 39(5):1327-1333.
41. Basse N, et al. (2010) Toward the rational design of p53-stabilizing drugs: Probing the surface of the oncogenic Y220C mutant. Chem Biol 17(1):46-56.
42. Barelier S, Pons J, Gehring K, Lancelin J-M, Krimm I (2010) Ligand specificity in fragment- based drug design. J Med Chem 53(14):5256-5266.
43. Chen I-J, Hubbard RE (2009) Lessons for fragment library design: Analysis of output from multiple screening campaigns. J Comput Aided Mol Des 23(8):603-620.
44. Turnbull WB, Daranas AH (2003) On the value of c: Can low affinity systems be studied by isothermal titration calorimetry? J Am Chem Soc 125(48):14859-14866.
45. Otwinowski Z, Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276:307-326.
46. Leslie AGW (1992) Recent changes to the MOSFLM package for processing film and image plate data. Joint CCP4 + ESF-EAMCB Newsletter on Protein Crystallography 26, 10.1073/ pnas.1114128109.
47. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihoodmethod. Acta Crystallogr D Biol Crystallogr 53(Pt 3):240-255.
48. Emsley P, Cowtan K (2004) Coot: Model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60(Pt 12 Pt 1):2126-2132.
49. DeLano WL (2008) The PyMOL Molecular Graphics System (DeLano Scientific LLC, San Carlos, CA).